Sign Pharma Trade Services Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 17 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.95 Cr
as on 23-10-2024
- Revenue 8.44%
(FY 2023)
- Profit 29.87%
(FY 2023)
- Ebitda 70.09%
(FY 2023)
- Net Worth 29.28%
(FY 2023)
- Total Assets -4.27%
(FY 2023)
About Sign Pharma Trade Services
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.95 Cr.
Dhiren Shah and Hiren Doshi serve as directors at the Company.
- CIN/LLPIN
U51397MH2007PTC174485
- Company No.
174485
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Sep 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sign Pharma Trade Services Private Limited offer?
Sign Pharma Trade Services Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Chemical Reagents & Catalysts, Inorganic Salts, Pharma Ingredients & Raw Materials, Anti Infective API, Industrial Chemicals & Supplies, Biocides, Anti Infective Drugs & Medicines, Malaria Medicine.
Who are the key members and board of directors at Sign Pharma Trade Services?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhiren Shah  | Director | 25-Sep-2007 | Current |
| Hiren Doshi | Director | 25-Sep-2007 | Current |
Financial Performance of Sign Pharma Trade Services.
Sign Pharma Trade Services Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.44% increase. The company also saw a substantial improvement in profitability, with a 29.87% increase in profit. The company's net worth Soared by an impressive increase of 29.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sign Pharma Trade Services?
In 2023, Sign Pharma Trade Services had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Feb 2020 | ₹5.19 Cr | Open |
Hdfc Bank Limited Creation Date: 06 Oct 2017 | ₹3.76 Cr | Open |
How Many Employees Work at Sign Pharma Trade Services?
Unlock and access historical data on people associated with Sign Pharma Trade Services, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sign Pharma Trade Services, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sign Pharma Trade Services's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
